VOGLISUG-GM-2/1000 TABS
MRP: 2
Packaging: 10X15
Pack Type: tablet
Composition:
Voglibose 0.2mg + Glimepiride 2mg + Metformin HCL 1000
Indication:
for the treatment of type 2 diabetes mellitus in adults to achieve better blood sugar control, particularly in patients not adequately controlled with dual therapy.
Description:
This triple drug combination—Voglibose 0.2 mg + Glimepiride 2 mg + Metformin HCl 1000 mg (Sustained Release)—is formulated for the effective management of type 2 diabetes mellitus (T2DM). It targets multiple pathophysiological defects in diabetes including insulin resistance, impaired insulin secretion, and postprandial hyperglycemia.
Metformin (1000 mg SR) improves insulin sensitivity and reduces hepatic glucose output.
Glimepiride (2 mg) stimulates insulin secretion from pancreatic β-cells.
Voglibose (0.2 mg) delays carbohydrate absorption from the intestine, thereby controlling post-meal glucose spikes.
Tags:
- Controls fasting and postprandial blood glucose
- Targets insulin resistance, insulin secretion, and carbohydrate absorption
- Reduces glycemic variability
- Once-daily dosing improves compliance
Usage Information
Dosage
Recommended Dose: 1 tablet once daily with or after a major meal Do not crush or chew (due to SR formulation of Metformin) Dosage should be individualized as per physician advice Monitor blood sugar levels regularly
Side Effects
Hypoglycemia (especially if meal is skipped) Gastrointestinal discomfort: bloating, diarrhea (mostly due to Metformin) Weight gain (from Glimepiride) Flatulence (from Voglibose) Rare: Lactic acidosis (with Metformin in renal dysfunction)
Contraindications
Type 1 diabetes mellitus Diabetic ketoacidosis or metabolic acidosis Severe renal or hepatic impairment History of sulfonylurea allergy (Glimepiride) GI disorders like IBD or chronic colonic diseases (Voglibose caution)